Donanemab-azbt bulk supplier for pharma manufacturers

Donanemab-Azbt 350 mg/20 mL Suppliers & Bulk Manufacturers

Available Forms: Injection

Available Strengths: 350 mg/20 mL

Reference Brands: Kisunla(USA)

Category: Neurology

Donanemab-azbt is a humanized immunoglobulin G1 monoclonal antibody directed against insoluble, N‑truncated pyroglutamate amyloid‑beta found in amyloid plaques in the brains of patients with Alzheimer’s disease. Its mechanism involves binding to these amyloid plaques and facilitating their removal (via microglial-mediated phagocytosis), thereby reducing amyloid burden in the brain. Use of donanemab has been shown to slow cognitive and functional decline in adults with early symptomatic Alzheimer’s disease (mild cognitive impairment or mild dementia) who have confirmed amyloid pathology.

Ask About Access

Usually answered within 48 hours | GMP documents shared before you commit

Manufacture or export Donanemab-Azbt? List it or send an offer →

Product Description:

Donanemab is an antibody against a modified form of amyloid-beta — N-truncated pyroglutamate amyloid-beta, found only in deposited plaque. Because it targets established plaque rather than soluble species, it clears amyloid rapidly, and the trial design used that: treatment was stopped once PET imaging showed plaque had fallen below a set threshold, making it one of the few Alzheimer's therapies with a defined end point rather than indefinite infusion. The trial showed slower clinical decline over eighteen months in early symptomatic Alzheimer's disease with confirmed amyloid pathology.

The dominant risk is amyloid-related imaging abnormalities: brain oedema and microhaemorrhage, usually asymptomatic but occasionally serious or fatal. Risk is highest in APOE ε4 homozygotes, which is why genotyping is part of eligibility. MRI monitoring is scheduled around the early infusions, and anticoagulation raises bleeding concern.

Sourcing notes. Originator biologic, on patent, no biosimilar. Authorised in the US, and in the EU after an initial refusal, where use excludes APOE ε4 homozygotes; other markets differ and are still evolving. Use depends on infrastructure most markets do not yet have at scale — amyloid PET or CSF biomarkers, APOE genotyping and serial MRI — so a buyer without that pathway cannot use the product. Treat enquiries as authorised-distributor or named-patient supply. Cold chain.

How Donanemab-Azbt is supplied today, and licensing ahead of patent expiry

Donanemab-Azbt is a patented innovator medicine. Where its patents are in force, which today includes most major markets, it can only be supplied by the originator or its licensees, through the routes below. Patents do expire, though, and generic development and licensing deals for post-patent markets start years in advance. If you are developing Donanemab-Azbt, hold a dossier for it or want to license it, talk to us.

Named-patient import Where a patient needs the product in a market where it is not registered, named-patient import is the lawful route. It requires the treating physician's documentation and authorisation from the destination regulator. We handle this pathway. Named-patient access

Authorised distribution For registered markets, supply runs through the manufacturer's authorised distribution channel. We can identify the authorised route for your market and tell you whether the product is registered there at all. Innovator sourcing

A genericised alternative Where the clinical requirement is the drug class rather than this specific molecule, there is often an off-patent alternative that is faster to register and materially cheaper. Tell us the indication and target market and we will say plainly whether one exists. Discuss alternatives

Licensing and generic development Patents expire country by country, and in many countries development and dossier filing can start before expiry under research and regulatory-review exemptions. We connect manufacturers developing this molecule, dossier holders, licensees and tech-transfer partners for markets where it is, or will become, off-patent. Partner on this molecule

Ask about Donanemab-Azbt supply →

Back to Listing

Frequently Asked Questions

Donanemab (Kisunla) treats early symptomatic Alzheimer’s disease (mild cognitive impairment or mild dementia) in adults with confirmed amyloid pathology. The US FDA approved it in July 2024.

It is a humanised monoclonal antibody that binds a modified form of amyloid-beta found only in brain plaques, and helps the immune system clear those plaques.

Kisunla.

As an intravenous infusion every four weeks. Treatment can be stopped once scans show the plaques have been cleared below a set level.

Amyloid-related imaging abnormalities (ARIA): brain swelling or small bleeds, seen on MRI. The risk is higher in people with two copies of the APOE ε4 gene, so MRI checks are part of treatment.

Kisunla (Donanemab) is developed and sold by Eli Lilly. PharmaTradz handles enquiries for authorised supply of the originator product, named-patient import where it is not registered, and licensing or development work ahead of patent expiry.